INDUSTRY AND SATELLITE SYMPOSIA GUIDE

www.idf.org/congress Sano -sponsored Symposium on the Occasion of the International Diabetes Federation Congress 2017, Abu Dhabi, United Arab Emirates EVOLVING STRATEGIES FOR EARLY, EFFECTIVE GLYCEMIC CONTROL IN TYPE 2 DIABETES

Tuesday 5 December 2017 17:30 –19:30

Conference Hall A Abu Dhabi National Exhibition Centre

Congress

4-8 December Abu Dhabi Date of Approval: October 2017 | SAGLB.DIA.17.10.1457a

786209073_Sanofi_Symposium Ad_CC01.indd 1 18/10/2017 10:24 INDUSTRY AND SATELLITE SYMPOSIA GUIDE

www.idf.org/congress B:210 mm T:200 mm S:180 mm

In patients with type 2 diabetes and established CV disease,1-3* CV DEATH HAS A NEW OPPONENT RRR IN CV DEATH ON TOP OF STANDARD 1,2† HR=0.62 OF CARE (95% CI: 0.49, 0.77) P<0.001

Learn more about the JARDIANCE CV data at Booth K30 B:210 mm T:200 mm S:180 mm

* Adult patients with insuffi ciently controlled type 2 diabetes (HbA1c 7-10%) and established CV disease References: 1. JARDIANCE [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer Ingelheim including coronary artery disease, peripheral artery disease, or a history of myocardial infarction or stroke.1-3 International GmbH; July 2017. 2. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empaglifl ozin, † 1,2 cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. 3. Zinman B, Inzucchi SE, Lachin Standard of care included CV medications and glucose-lowering agents given at thediscretion of physicians. JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of CI=confi dence interval; HR=hazard ratio; RRR=relative risk reduction. empaglifl ozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol. 2014;13(102). doi:10.1186/1475-2840-13-102. JARDIANCE is a prescription medicine indicated for the treatment of adults with insuffi ciently controlled must be considered in the event of non-specifi c symptoms such as nausea, vomiting, anorexia, abdominal type 2 diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is considered pain, excessive thirst, diffi culty breathing, confusion, unusual fatigue or sleepiness. Patients should be inappropriate due to intolerance, in addition to other medicinal products for the treatment of diabetes. assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level. In For EMPA-REG OUTCOME® study results with respect to combinations, effects on glycaemic control and patients where DKA is suspected or diagnosed, treatment with empaglifl ozin should be discontinued cardiovascular events, and the populations studied only. JARDIANCE is not for people with type 1 diabetes immediately; restarting SGLT2 inhibitor treatment in patients with previous DKA while on SGLT-2 inhibitor or for people with diabetic ketoacidosis. The recommended starting dose is 10 mg empaglifl ozin once treatment is not recommended. Haematocrit increase was observed with empaglifl ozin treatment. The daily for monotherapy and add-on combination therapy with other medicinal products for the treatment of effect of empaglifl ozin on urinary glucose excretion is associated with osmotic diuresis, which could affect diabetes. In patients tolerating empaglifl ozin 10 mg once daily who have an eGFR≥ 60 ml/min/1.73 m2 and the hydration status. Patients aged 75 years and older may be at an increased risk of volume depletion. A need tighter glycaemic control, the dose can be increased to 25 mg once daily. The maximum daily dose is higher number of these patients treated with empaglifl ozin had adverse reactions related to volume depletion 25 mg. When empaglifl ozin is used in combination with a sulphonylurea or with insulin, a lower dose of the as compared to placebo. Therefore, special attention should be given to their volume intake in case of sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia. The tablets can be taken co-administered medicinal products which may lead to volume depletion (e.g. diuretics, ACE-inhibitors). with or without food, swallowed whole with water. If a dose is missed, it should be taken as soon as the Urinary tract infections, in a pool of placebo-controlled double-blind trials of 18 to 24 weeks duration, the patient remembers. A double dose should not be taken on the same day. In patients tolerating empaglifl ozin overall frequency of urinary tract infection reported as adverse event was similar in patients treated with whose eGFR falls persistently below 60 ml/min/1.73 m2 or CrCl below 60 ml/min, the dose of empaglifl ozin empaglifl ozin 25 mg and placebo and higher in patients treated with empaglifl ozin 10 mg. Complicated should be adjusted to or maintained at 10 mg once daily. Empaglifl ozin should be discontinued when eGFR urinary tract infections (including serious urinary tract infections, pyelonephritis or urosepsis) occurred at is persistently below 45 ml/min/1.73 m2 or CrCl persistently below 45 ml/min. Empaglifl ozin should not be a similar frequency in patients treated with empaglifl ozin compared to placebo. Temporary interruption of used in patients with end stage renal disease (ESRD) or in patients on dialysis as it is not expected to be empaglifl ozin should be considered in patients with complicated urinary tract infections. An increase in effective in these patients. No dose adjustment is required for patients with hepatic impairment. Empaglifl ozin cases of lower limb amputation (primarily of the toe) has been observed in ongoing long-term clinical studies exposure is increased in patients with severe hepatic impairment. Therapeutic experience in patients with with another SGLT2 inhibitor. It is unknown whether this constitutes a class effect. Like for all diabetic severe hepatic impairment is limited and therefore not recommended for use in this population. No dose patients it is important to counsel patients on routine preventative foot care. The tablets contain lactose. adjustment is recommended based on age. In patients 75 years and older, an increased risk for volume Patients with rare hereditary problems of galactose intolerance, the Lapp lactase defi ciency, or glucose- depletion should be taken into account. In patients aged 85 years and older, initiation of empaglifl ozin therapy galactose malabsorption should not take this medicinal product. is not recommended due to the limited therapeutic experience. The safety and effi cacy of empaglifl ozin in Drug Interactions: Empaglifl ozin may add to the diuretic effect of thiazide and loop diuretics and children and adolescents has not yet been established. may increase the risk of dehydration and hypotension. Insulin and insulin secretagogues, such as Contraindications: Hypersensitivity to the active substance or to any of the excipients. sulphonylureas, may increase the risk of hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination Special warnings and precautions for use: General; Jardiance should not be used in patients with type 1 with empaglifl ozin. diabetes or for the treatment of diabetic ketoacidosis. Diabetic ketoacidosis: Rare cases of diabetic ketoacidosis (DKA), including life-threatening and fatal cases, have been reported in patients treated with The most common side effects of JARDIANCE include urinary tract infections and yeast infections SGLT2 inhibitors, including empaglifl ozin. In a number of cases, the presentation of the condition was in females. atypical with only moderately increased blood glucose values, below 14 mmol/l (250 mg/dl). It is not known Revision date: August 2017. if DKA is more likely to occur with higher doses of empaglifl ozin. The risk of diabetic ketoacidosis Please refer to the country approved indications and full Prescription Information. NEM/TRA-171039

NEM/TRA-171039_IDF_Journal_Ad_FR.indd 1 9/13/17 12:17 PM

PREPARED BY AREA 23 Releasing as: PDFX-1a Production: Frank LaPort x2631 Job #: 10784664 AD: David Figueroa x2663 Colors: 4C Client: BI AE: Philippe Freund x2545 Product: Jardiance Global Bleed: 210 mm x 210 mm Producer: Adolfo Zepeda x6843 Client Code: NEM/TRA-171039 Trim: 200 mm x 200 mm Digital Artist: CL, CL, CL, CL Date: September 13, 2017 12:12 PM Safety: 180 mm x 180 mm Add’l Size Info: Proof: FR Fonts: Interstate, Helvetica Neue LT Std, M1 Spellcheck: SB Minion Pro, ITC Franklin Gothic FR Spellcheck: NC Path: Area23:BI:EMPA:10784664:Packaged_Jobs:NEM/TRA-171039_IDF_Journal_Ad:NEM/TRA-171039_IDF_Journal_Ad_FR 4C JAR GB IDF Journal Ad TABLE OF CONTENTS

Congress-at-a-glance 6 Acknowledgements 7 Satellite symposia overview 7 Venue location map 10 Venue map 12 Floor plans 14 Exhibitors 18 Company profiles 19 Satellite symposia 29

The content of this publication reflects the situation at the time of print and may be subject to change. The organiser cannot be held liable for any inconvenience resulting from these changes. 5 CONGRESS-AT-A-GLANCE

Monday 4 Dec Tuesday 5 Dec Wednesday 6 Dec Thursday 7 Dec Friday 8 Dec

08.00 Scientific Scientific Scientific Scientific Sessions Sessions Sessions Sessions 09.00

09.30 coffee break coffee break coffee break 10.00 Satellite Symposia Scientific Scientific Scientific Scientific Sessions Sessions Sessions Sessions

11.30 11.45

Lunch Meet the 12.30 session speaker Satellite Satellite Satellite Symposia Symposia Symposia

IDF General Sessions Poster Sessions Poster Sessions Poster Assembly Satellite 12.45

Symposia Exhibition Exhibition Exhibition 13.15 Scientific Scientific Scientific Scientific Sessions Sessions Sessions Sessions 14.30

14.45 coffee break coffee break coffee break 15.15 15.30 Scientific Scientific Scientific Sessions Sessions Sessions Satellite 16.45 Symposia 17.00 17.30

Satellite Satellite Satellite 18.30 Symposia Symposia Symposia

19.00 5K@IDF 19.30 20.30 Opening Farewell evening Farewell 22.00 6 ACKNOWLEDGEMENTS

The Organising Committee of the IDF 2017 Congress expresses its appreciation and recognition to the following organisations for their support:

Abu Dhabi Convention Bureau

Abu Dhabi Department of Culture and Tourism

Abu Dhabi Department of Health

Abu Dhabi Department of Transport

SATELLITE SYMPOSIA OVERVIEW

MONDAY 4 DECEMBER 12:30 - 14:30 Conference Hall A Lilly Diabetes The transition to injectable therapies: Navigating clinical and emotional challenges in T2DM

15:30 - 17:30 Conference Hall A Boehringer Ingelheim Improving cardiovascular outcomes in patients with type 2 diabetes: Applying new evidence in practice

15:30 - 17:30 Conference Hall B Takeda Shaping the future of type 2 diabetes management: What next?

7 TUESDAY 5 DECEMBER 11:45 - 12:45 Conference Hall B Roche Diabetes Care Shaping the future of integrated diabetes management solutions and clinical treatment for patients with type 2 diabetes

12:00 - 13:00 Diabetes Spotlight Sanofi Pasteur Impact of influenza on people living with diabetes: A serious and under-appreciated threat

17:30 - 19:30 ICC 1 AstraZeneca Precision medicine for Type 2 diabetes

17:30 - 19:30 ICC 4 MSD 10 years of DPP-4 inhibition: Understanding new science and clinical treatment for patients with type 2 diabetes

17:30 - 19:30 Conference Hall A Sanofi Evolving strategies for early, effective glycemic control in Type 2 diabetes

17:30 - 19:30 Conference Hall B Novo Nordisk Next generation of ultra-long acting insulins in type 2 diabetes

17:30 - 19:30 Capital Suite 1 Advancing an integrated model of quality eye care, diabetes and NCDs

18:30 - 20:30 Hall 11 Novo Nordisk Cardiovascular outcome trials: closing a gap in management of type 2 diabetes?

8 WEDNESDAY 6 DECEMBER 11:45 - 12:45 Conference Hall B Novartis Fighting clinical inertia: When and how

12:00 - 13:00 Diabetes Spotlight Sanofi Let’s talk about basal insulin: Taking a three-dimensional approach

13:30 - 14:30 Diabetes Spotlight Dexcom/Julphar Continuous glucose monitoring (CGM): The emerging global standard of care for glucose monitoring

17:30 - 19:30 Conference Hall A Servier Tackling unmet needs in type 2 diabetes: Evolving perspectives

17:30 - 19:30 Conference Hall B Novo Nordisk The pursuit of ultra-fast insulins

17:30 - 19:30 Capital Suite 1 D&CVD EASD Study Group & Forschergruppe Diabetes Diabetic complications: Challenges and opportunities, Hellmut Mehnert Award

THURSDAY 7 DECEMBER 12:00-13:00 Diabetes Spotlight Sanofi Fixed-ratio combinations: a practical approach to individualised care

13:30 - 14:30 Diabetes Spotlight International Hypoglycaemia Study Group Hypoglycaemia: a practical approach to a global problem

17:30 - 19:30 Conference Hall B Novo Nordisk Targeting weight and comorbidities via the GLP-1 receptor

9 VENUE LOCATION MAP

10 11 ADNEC Site Map LEGEND Halls Car Parking Capital Suites Lift Conference Rooms Food Court VENUE MAP Central Plaza Escalator Security Gates Reception Desk Concourse Entrance Food & Beverage Security House ATM 6 Clinic 7 Al KARAMAH ST. 5 4 HYATT CAPITAL GATE 8 3 10 9 11

ICC 8 G F 7 H E 6 D J 5 Al Maa’red Atrium K A C L 4 aloft B B 3 VIP Entrace 2 KHALEEJ AL ARABI ST. ADNEC 1 R/A A 33rd St. ADNEC MARINA 1 2 Marina Bridge

TO ABU DHABI CITY TO ABU DHABI AIRPORT / DUBAI

12 ADNEC Site Map LEGEND Halls Car Parking Capital Suites Lift Conference Rooms Food Court Central Plaza Escalator Security Gates Reception Desk Concourse Entrance Food & Beverage Security House ATM 6 Clinic LegendLEGEND Venue Map ADNEC Site Map7 Al KARAMAH ST. 5 Halls Car Parking 4 HYATT CAPITAL GATE Capital Suites Lift 8 10 3 Conference Rooms Food Court 9 11 Central Plaza ICC Escalator 8 G Security Gates F Reception Desk 7 H Concourse Entrance E Food & Beverage 6 Security House D J ATM 5 6 Al Maa’red Atrium K Clinic A C 7 L Al KARAMAH ST. 4 5 aloft B 4 B HYATT CAPITAL GATE 3 8 VIP Entrace 10 3 2 KHALEEJ AL ARABI ST. 9 ADNEC 11 1 R/A ICC A8 G F 33rd St. 7 H ADNEC MARINA 1 E 2 6 D J Marina Bridge 5 Al Maa’red Atrium K A C L 4 aloft B TO ABU DHABI CITY B TO ABU DHABI AIRPORT / DUBAI 3 VIP Entrace 2 KHALEEJ AL ARABI ST. ADNEC 1 R/A A 33rd St. ADNEC MARINA 1 2 13 Marina Bridge

TO ABU DHABI CITY TO ABU DHABI AIRPORT / DUBAI FLOOR PLAN

Hall 10 5 Car Park B CS16 CS17 CS15 4 CS18 Hall 11 6 Hall 9 CS19 CS14 CS20 CS13 G F ICC Abu Dhabi Car Park A CS12 7 Hall 8 H CS11

CS10 E

CS9 J Hall 7 CS21 9 CS8 i D Central Plaza F i K Hall 6 L 10 Hall 5 M C 1 CS7 The Atrium CS6 Al Maa’red Hall Conference Hall A CS5 2 CS4 B Hall 4 The Link CS3 CS2 Conference Hall B Hall 3 2 CS1 Hall 2 The Grandstand

Hall 1 A

14 Hall 10 Car Park B CS16 Legend Ground floor CS17 CS15 4 CS18 Hall 11 Hall 9 CS19 1 Registration & Congress bag counter CS14 CS20 3 CS13 G F ICC Abu Dhabi Car Park A 1 5K@IDF registration / Start & Finish CS12 2 Session halls Hall 8 H CS11 3 Session halls ICC 1-2-3-4 /

CS10 E Opening Ceremony

CS9 J 4 Session hall Hall 7 CS21 CS8 i D Central Plaza 5 Global Village/poster area F i 8 K 6 Exhibition / Diabetes Spotlight Hall 6 L 7 Lunch bag catering Hall 5 C M 8 Speaker preview room CS7 The Atrium CS6 Al Maa’9red First Aid Hall Conference Hall A CS5 CS4 B Hall 4 The Link CS3 CS2 Conference Legend Mezzanine Floor Hall B Hall 3 CS1 11 10 Media Centre

Hall 2 11 CS 1 - Satellite meetings The Grandstand CS 2 CS 5 Hall 1 CS 8 Hospitality Suites A CS 11 CS 12 CS 7 Corporate meeting room CS 14 IDF meeting room CS 18 IDF Volunteers

15 EXHIBITION FLOOR PLAN

VE VE VE VE VE VE VE VE DOOR DOOR DOOR DOOR DOOR DOOR DOOR DOOR 8.1 8.2 8.3 8.4 9.3 10.1 9.1 9.2

DIVIDER CATERING CATERING LOADING CATERING ADNH CATERING LOADING ADNH PLANT PLANT STORE LOADING STORE LOADING ROOM ROOM BAY ROOM STORE STORE BAY STORE ROOM ROOM ROOM BAY ROOM BAY

ICT ROOM

319 Poster Boards 638 Faces viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face 638 viewing face 630 viewing face 622 614 viewing face 606 viewing face 594 viewing face 582 viewing face 570 viewing face 558 viewing face 546 viewing face 534 viewing face 522 viewing face 510 viewing face 498 486 viewing face 474 462 viewing face 450 viewing face 438 viewing face 426 414 viewing face 402 viewing face

SUBSTATION viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face Poster help viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face 2 viewing face 2 desk viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face

LV SWITCH J34 J35 J36 J37 Searl Optomed EASD Company Gabric

MV SWITCH

L35 L36 L37 L34 M40 P30 viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face 4 viewing face viewing face viewing face viewing face 390 378 366 354 342 330 Owenmumford AACE Sunstar N34 Hikma viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face Phamaceuticals viewing face J30 K30 viewing face viewing face viewing face N32 viewing face viewing face viewing face viewing face viewing face Alere viewing face viewing face viewing face viewing face Novartis viewing face viewing face viewing face L30 M30 viewing face viewing face viewing face viewing face Lilly Boehringer Ingelheim viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face Evia Medical viewing face viewing face viewing face viewing face viewing face viewing face Julphar viewing face Technologies N30

Neopharma viewing face viewing face viewing face viewing face viewing face viewing face Diabetes Spot Light viewing face viewing face viewing face viewing face viewing face viewing face

SUBSTATION

SUBSTATION viewing face viewing face viewing face viewing face ST9 A26 C26 D26 E26 E28 F20 G20 K20 L20 L24 M20 N26 viewing face viewing face viewing face viewing face viewing face Diabetik 318 viewing face 306 294 viewing face 282 viewing face 270 viewing face 258 246 viewing face Lilly Foot Care NeoBiocon Glenmark Exevia India Catering Area/ SAJ Acon viewing face viewing face viewing face viewing face viewing face viewing face viewing face Indian Food/ viewing face viewing face viewing face viewing face viewing face viewing face viewing face ST8 A24 J10 TO GO Laboratories Dasman WOKINAKI viewing face Lilly Diabetes Servier viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face Institute Tonghua Imperial College viewing face viewing face Dongbao London Diabetes Roche Merck LG Chem viewing face viewing face viewing face A22 C20 D20 E20 viewing face viewing face viewing face viewing face viewing face viewing face The Diabetes Pharmaceutical Centre viewing face viewing face viewing face viewing face viewing face ST7 Centre viewing face viewing face viewing face viewing face viewing face viewing face Busan Tourism SAJ viewing face viewing face viewing face viewing face viewing face viewing face viewing face Seating viewing face A20 Organisation TO GO 5 N20 Cambridge

Weight Plan Pic Solution P20 viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face ST6 Catering Area/ Coffee Bike/ RUSH viewing face viewing face viewing face 5 H12 ST5 Novo Nordisk

A18 D16 D17 E10 F10 G10 H10 N10 P10 viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face Insulin Novo 234 222 210 viewing face 198 186 174 Seating ST4 for life Nordisk viewing face viewing face viewing face Novo viewing face viewing face viewing face viewing face viewing face viewing face viewing face Nordisk A16 D14 D15 K10 L10 M10 viewing face viewing face WUWHS2020 viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face ST3 viewing face Novo Ascencia VE DOOR Wellbeing Zone Trividia Health Sanofi Novo Nordisk IDF viewing face viewing face viewing face viewing face viewing face Nordisk A12 D12 D13 Diabetes Care viewing face 10.2 viewing face viewing face viewing face viewing face World viewing face viewing face Diabetes AstraZeneca Becton Dickinson Abu Dhabi TCA ST2 Foundation viewing face viewing face viewing face viewing face Novo viewing face viewing face viewing face viewing face viewing face viewing face viewing face Nordisk A10 D10 D11 viewing face

Inbody viewing face viewing face viewing face viewing face viewing face viewing face LOADING BAY ST1 viewing face viewing face viewing face viewing face viewing face viewing face Novo VE DOOR Nordisk 10.3 viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face R30 162 viewing face 150 viewing face 138 viewing face 126 viewing face 114 viewing face 102 viewing face 90 viewing face 78 viewing face R26 R28 KITCHEN KITCHEN R24 DIVIDER VE DOOR DIVIDER DIVIDER R22 R20 viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face DIVIDER STORE STORE R18 STORE viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face STORE ROOM ROOM R16 R31 ROOM ROOM R14 R29 R12 R27 10.4 R10 R23 R25 viewing face R19 R21 viewing face viewing face viewing face viewing face viewing face viewing face viewing face R15 R17 viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face ELECT ICT R13 ROOM R11

ORGANISERS viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face ORGANISERS viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face MEDICAL OFFICE HALL OFFICE HALL S30 ICT ELECT S28 viewing face viewing face viewing face viewing face viewing face viewing face viewing face CENTRE ROOM S26 viewing face viewing face viewing face viewing face viewing face viewing face 8 9 S22 S24 viewing face viewing face viewing face VISITORS VISITORS VISITORS S18 S20 OPERATION S14 S16 S29 S31 CATERING S12 S27 viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face

ELV ELV OFFICE S10 S25 viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face S21 S23 ROOM ENTRANCE ROOM ENTRANCE ROOM S19 ENTRANCE VISITORS S15 S17 S11 S13 REVA REV A ENTRANCE T28 T30 T24 T26 viewing face viewing face viewing face viewing face viewing face viewing face viewing face T22 viewing face viewing face viewing face viewing face viewing face viewing face viewing face IDF 5K T20 66 58 50 40 30 20 10 Information T16 T18 T31 booth T14 T29 T10 T12 T25 T27 viewing face viewing face viewing face viewing face viewing face viewing face viewing face 6 T21 T23 viewing face viewing face viewing face viewing face viewing face viewing face viewing face T19 T15 T17 viewing face viewing face viewing face viewing face viewing face viewing face T11 T13 viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face

DIVIDER

viewing face viewing face viewing face viewing face viewing face viewing face viewing face STORE

U28 U30 viewing face viewing face viewing face viewing face viewing face viewing face viewing face ROOM U24 U26 U20 U22 viewing face viewing face viewing face U18 viewing face viewing face

MEDIA U31 DIVIDER viewing face viewing face viewing face U16 viewing face viewing face SITE STORE U29 ROOM U12 U14 U27 U10 U23 U25

MEDIA U21 SITE U19 Catering U15 U17 ORGANISERS U13 Outlet '9' OFFICE HALL U11

V32 V33 V28 V30 10 V26 V22 V24 V18 V20 V14 V16 KITCHEN V10 V12

(TEMPORARY) T11-A RECEPTION AT M

MEDIA SITE ET 4 MEDIA SITE ET 5 Outlet '6' Catering ENTRANCE F

REV 11.1 A MACHIN E COFFEE

16 17 Diabetes spotlight sessions area and e-poster Poster Global Village Lunch bag catering trucks Food IDF info booth Legend 1 2 3 4 5 6

VE DOOR VE DOOR 10.4 VE DOOR 10.3 10.2 DIVIDER STORE CATERING ROOM ROOM LOADING BAY SUBSTATION MV SWITCH

SUBSTATION SUBSTATION

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing LV SWITCH viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face 10

78

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing ROOM viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face STORE 90 20

246 174

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face 30

102 330 258 186 402

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face 40

114 198 342 270 414

viewing face viewing face viewing viewing face viewing face viewing viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing viewing face viewing viewing face viewing viewing face viewing face viewing viewing face viewing ROOM face viewing PLANT

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face 50 126 354 282 210 426 2 ICT

ROOM

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face 58 138 222

366 294 438

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face 66 378 306 450 150

234

T11-A

viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face viewing face V33

162 390 318 462

V32

viewing face viewing viewing face viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face

V30

1 U3

0 U3 474

2

1 T3

T30 8 V2

9 U2

S31

S30 U28

viewing face viewing face viewing face viewing face viewing face viewing face viewing

T29 1 viewing face viewing face viewing face viewing face viewing face viewing face R3

ROOM V26 8 T2

0 PLANT R3

U27 S29

S28 U26

486

T27 R29

4 V2 T26 8 R2

7 S2

U25

S26 U24

viewing face viewing face viewing face viewing face viewing face viewing viewing face viewing

5 T2 7

viewing face viewing face viewing face viewing face viewing face viewing face R2

V22 4 T2 6 R2

5 S2 3 U2

3

4 S2 2 U2

498

3 T2 R25

V20 2 T2 R24

1 U2 S23

S22

U20

viewing face viewing face viewing face viewing face viewing face viewing face viewing

1 T2

3

viewing face viewing face viewing face viewing face viewing face viewing face R2

8 V1 0 T2 R22

9 U1 1 S2

0 S2 8 U1

510

9 T1 1 R2

V16 8 T1 0 R2

S19 7 1 U1

8 S1 U16

viewing face viewing face viewing face viewing face viewing face viewing face viewing

T17 R19

viewing face viewing face viewing face viewing face viewing face viewing face

V14 T16 R18

U15

7 S1

Diabetes Spot Light

4 U1 6 S1

IDF 522

T15 7 R1

2 V1 4 T1 6 R1

5

5 S1 3 U1

4 S1 2 U1

viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing 3 Catering Area/ Coffee Bike/ RUSH T1 5 R1

viewing face viewing face viewing face viewing face viewing face viewing face

V10 2 T1 4 R1

S13

1 U1

S12

0 U1

534

T11 R13

T10 2 R1

S11

0 S1

R11 viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face

0 R1 P20 P10 P30 546

VE KITCHEN 10.1 DIVIDER DOOR STORE ROOM desk

Acon Alere Hikma

Ascencia Poster help

Neopharma Pic Solution

Laboratories

Diabetes Care N10

N20 N26

N30 N32

N34 Phamaceuticals

BAY VE

9.3 ORGANISERS

L R DOO 11.1 LOADING OFFICE HAL 10

COFFEE MACHINE Sunstar ADNH LG Chem STORE Evia Medical Technologies M20 M30 M40 638 Faces Abu Dhabi TCA 319 Poster Boards M10 VISITORS

ENTRANCE

viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face ROOM STORE Merck DIVIDER Novartis 558 L24 L34 ROOM STORE OFFICE DIVIDER

OPERATION

viewing face viewing face viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face

570

viewing face viewing face viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face L37 Becton Dickinson 582 Roche AACE L20 L36 L10

Catering

Outlet '9'

viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face Julphar

594

viewing face viewing face viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face viewing face viewing face SAJ SAJ Owenmumford TO GO TO GO L35 L30 606

REVAREVA 9 OFFICE HALL ORGANISERS AstraZeneca KITCHEN Centre K10 MEDIA SITE ET 5 BAY VE 9.2 DOOR Imperial College LOADING London Diabetes Boehringer Ingelheim K20 K30 ELV ICT ROOM ROOM ROOM ELECT STORE DIVIDER

ATM VE 9.1

DOOR

viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face 614 Gabric

J37

viewing face viewing viewing face viewing face viewing face viewing viewing face viewing face viewing face viewing face MEDIA SITE STORE Searl 622 CATERING Company J36 Lilly

Novo Nordisk

viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face EASD J35 630 ADNH STORE VISITORS

ENTRANCE

viewing face viewing face viewing face viewing face viewing

viewing face viewing face viewing face viewing face J10 J34 J30 Optomed 638 ENTRANCE F Novo Nordisk H10 H12 VISITORS ENTRANCE

RECEPTION Servier booth IDF 5K (TEMPORARY) Information ICT ELV ROOM STORE DIVIDER ROOM ROOM ELECT ROOM Sanofi

CATERING MEDIA SITE KITCHEN MEDIA SITE ET 4 G20 G10 VE 8.4 8 DOOR OFFICE HALL ORGANISERS VE 8.3 BAY Tonghua DOOR Dongbao LOADING Trividia Health F20 F10 Pharmaceutical

A REV VE 8.2 DOOR Exevia E28 Organisation Glenmark Busan Tourism E10 E26 E20 Wellbeing Zone D17 D15 D13 D11 Catering CENTRE MEDICAL Outlet '6' Seating NeoBiocon Novo D16 D14 D12 D10 D26 D20 Nordisk ROOM STORE DIVIDER BAY Seating WOKINAKI LOADING Indian Food/ Catering Area/ C20 C26 VE 8.1 DOOR Centre India World Institute Cambridge Dasman Diabetik Diabetes Diabetes Weight Plan for life Insulin The Diabetes Inbody Foot Care WUWHS2020 A18 A24 A22 A20 A16 A12 A10 A26 Foundation ROOM VISITORS CATERING ENTRANCE ROOM Lilly Lilly Novo Novo Novo Novo Nordisk Nordisk CATERING ST9 ST8 ST7 ST6 ST5 ST4 ST3 ST2 ST1 Nordisk Nordisk EXHIBITORS

Company Booth Company Booth Abu Dhabi Convention Bureau M10 Optomed Oy J34 Acon Laboratories N26 Owen Mumford L35 Alere N32 Pic Solutions N20 American Association of Clinical Endocrinologists (AACE) L36 Roche Diabetes Care L20 Ascensia N10 Sanofi G10 AstraZeneca K10 Servier G20 Becton Dickinson L10 Sunstar Suisse SA M40 Boehringer Ingelheim K30 The Diabetes Centre A22 Busan and Korean Tourism Organisation E20 The European Association for the Study of Diabetes J35 Cambridge Weight Plan A20 The Searle Company J36 Dasman Diabetes Institute A24 Tonghua Dongbao Pharmaceutical F20 Diabetik Foot Care India A26 Trividia Health F10 Evia Medical Technologies M30 World Diabetes Foundation A12 Exevia E28 WUWHS2020 A16 Gabric J37 Glenmark E26 Hikma Pharmaceuticals N34 Imperial College London Diabetes Centre K20 Inbody A10 Insulin For Life A18 Julphar L30 LG Chem M20 Lilly Diabetes J30 Merck L24 NeoBiocon D26 Neopharma N30 Novartis L34 Novo Nordisk J10 Novo Nordisk H10 Novo Nordisk H12 Novo Nordisk D16

18 COMPANY PROFILES

Abu Dhabi Convention Bureau/Department American Association of Clinical of Culture and Tourism #M10 Endocrinologists # L36

Welcome to Abu Dhabi: the Host Destination of the IDF 2017 The American Association of Clinical Endocrinologists (AACE) Congress Abu Dhabi, the capital of the United Arab Emirates (UAE) represents more than 7,000 endocrinologists in the United States and and the largest of the seven emirates, has seen four decades of abroad. AACE is the largest association of clinical endocrinologists in remarkable growth and development. It is now the nexus between the world. A majority of AACE members are certified in endocrinology, west and east, the developed and developing and the present and the diabetes and metabolism and concentrate on the treatment of future, and it is the meeting point between ancient and modern. In patients with endocrine and metabolic disorders. Abu Dhabi a futuristic city lives hand in hand with ancient treasures. The American College of Endocrinology (ACE) is the educational and This is a destination where the past is preserved, cherished and scientific arm of the American Association of Clinical Endocrinologists respected while the future is meticulously planned and considered. (AACE). ACE is the leader in advancing the care and prevention All of this comes together to provide a truly world class destination of endocrine and metabolic disorders by: providing professional where you are able to easily gather while enjoying state of the art education and reliable public health information; recognizing facilities, modern infrastructure, and top level service. excellence in education, research and service; promoting clinical research and defining the future of clinical endocrinology. Acon Diabetes Care # N26 Visit our web site at www.aace.com

ACON Diabetes Care, a part of ACON Laboratories, Inc., is Ascensia Diabetes Care # N10 headquartered in San Diego, California, USA. For over 10 years, ACON Diabetes Care has been focused on providing Ascensia Diabetes Care is a global specialist diabetes care company, accurate, painless, and easy to use blood glucose monitoring systems dedicated to helping people with diabetes. Our mission is to empower and other related test systems to people with diabetes all over the people living with diabetes through innovative solutions that simplify world. Our products are sold in more than 130 countries worldwide and improve their lives. and are highly recommended by health care professionals and clinical Home to the world renowned CONTOURTM portfolio of blood glucose institutes. ACON Diabetes Care is also committed to delivering monitoring systems, our products combine advanced technology with diabetes care education to patients to help inform them of what they user-friendly functionality that help people with diabetes manage their can do to live a healthier life. condition. Our products are sold in more than 125 countries. Ascensia Diabetes Care was established in 2016 through the sale Alere Inc. # N32 of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care has around 1,700 employees and operations Alere believes that when diagnosing and monitoring health in 33 countries. For further information, please visit our website at: conditions, Knowing now matters™. Alere delivers on this vision by http://www.ascensia.com. providing reliable and actionable information through rapid diagnostic tests, enhancing clinical and economic health outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for infectious disease, cardiometabolic disease and toxicology. For more information on Alere, please visit www.alere.com. ‘

19 AstraZeneca # K10 Busan and Korea Tourism Organisation #E20 AstraZeneca is a global, science-led biopharmaceutical company that Korea, Beyond Meetings focuses on the discovery, development and commercialisation of Korea is one of the most spirited and colorful countries in the prescription medicines, primarily for the treatment of diseases in three world. In the short time following its impressive development, it has main therapy areas - Oncology, Cardiovascular & Metabolic Disease managed to maintain the delicate balance of its impressive history and Respiratory. and tradition whilst embracing modernity. The Company also is selectively active in the areas of autoimmunity, Designed to meet your business needs and leisure experiences, Korea neuroscience and infection. AstraZeneca operates in over 100 is a top convention destination offering delegates a chance to enjoy countries and its innovative medicines are used by millions of patients an outstanding meeting infrastructure, safe meeting venues, a variety worldwide. of unique sights and experiences, and much more. A host of 1988 Olympics, 2002 World Cup, and 2005 APEC Summit, BD #L10 Korea offers a world of opportunities, knowledge, and business growth. BD is a leading medical technology company that benefits countless lives worldwide. We advance health by improving the ways that Dynamic City Busan discovery, diagnostics and delivery of care are conducted. As Korea’s most popular coastal city, Busan is full of excitement With 45,000 employees at work in more than 50 countries, we and joy with festivals all year round. It is a world-class city where work in close collaboration with customers and partners to develop contemporary lifestyle meets long-standing history. Multilingual innovative products and solutions that enhance outcomes, better signage, sophisticated public transportation system, iconic skyscrapers, manage healthcare delivery costs, increase efficiencies, improve and ICT-based systems used throughout the city make Busan a healthcare safety, and expand access to health. Because we’ve comprehensive and convenient city. been doing this for over 100 years, our portfolio, leadership and Create an experience that is truly more than just business and partnerships make a difference for global healthcare. discover the very best Korea has to offer for the 2019 International Diabetes Federation Congress! Boehringer Ingelheim # K30 Cambridge Weight Plan # A20 Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Cambridge Weight Plan, based in the East Midlands of the United Boehringer Ingelheim stands for. Kingdom, manufactures formula food products (nutritionally Boehringer Ingelheim is one of the pharmaceutical industry’s top complete shakes, soups and bars) that are used in total or partial diet 20 companies and to this day remains family-owned. Day by day, replacement regimens providing energy intakes both under 800kcal/d some 50,000 employees create value through innovation for the and above 800kcal/d. three business areas human pharmaceuticals, animal health and Cambridge Weight Plan has collaborated with research scientists biopharmaceutical contract manufacturing. In 2016, Boehringer to generate gold-standard evidence for effective weight loss and Ingelheim achieved net sales of around 15.9 billion euros. With more maintenance, safety, health benefits, improved nutritional status and than three billion euros, R&D expenditure corresponds to 19.6 per improved cardiovascular risk status. Programmes are delivered by cent of net sales. trained Cambridge Consultants working in a community setting or by health care professionals. Cambridge Weight Plan is available in over

20 40 countries and is the only programme proven to deliver average ABI/TBI, Digital Biothesiometer, Neuropathy Analyser with Vibration weight losses of over 10kg (about 10%) of body weight and weight & Thermal, Cardiac Autonomic Neuropathy Dysfunction Analyser, maintenance for up to four years, with health benefits in pre-diabetes, Foot Imprinter, Podiascan, Electric Pedicure, LED IR Light Therapy, osteoarthritis, psoriasis, obstructive sleep apnoea and coronary artery Neuropathy Therapy Stimulator and Podiatry Chair. disease, and before bariatric surgery. Please visit www.diabeticfootcareindia.com to understand more about us. Dasman Diabetes Institute # A24 Evia Medical Technologies # M30 In pursuance to the wishes of H. H. Sheikh Jaber Al-Ahmed Al- Jaber Al-Sabah the late Amir of Kuwait (may he rest in peace) to present Evia Medical Technologies Limited established in 2000 is a leading his people with a valuable and timeless gift that would ensure manufacturer of innovative technologies in the field of diabetes. their health for generations to come, the Kuwait Foundation for the Innovation and cutting edge technology is the core of our business. Advancement of Sciences (KFAS) financed Dasman Diabetes Institute We manufacture a CE certified non-invasive Glucose meter - aiming for it to become one of the leading centers in the field of egm1000TM that relies on three basic technologies: ultrasonic, research in the Middle East. electromagnetic and thermal technologies by using a special On June 6th , 2006, H. H. the Amir of Kuwait, Sheikh Sabah Al-Ahmed algorithm. We also manufacture an “Off the Shelf” refrigeration Al-Jaber Al-Sabah inaugurated the world class Institute. With our unit for insulin and other drugs requiring cooling: EviaCool and Research, Medical and Operational divisions, we strive to attain EviaCoolPro maintain temperatures in accordance with Insulin high-impact translational research and integrate its findings to basic manufacturers’ specifications. medical practices. Evia is also a Master Distributor to the MENA region to other Mission: To prevent, control and mitigate the impact of diabetes and manufacturers, and we are proud to represent Wound Care Medical, related conditions in Kuwait, through effective programs of research, the manufacturers of a Wound Healing Technology called SOZO. training, education and health promotion and thereby improve the Evia = Quality of Life2 quality of life. Vision: To be the leading diabetes institute in the Middle East. Exevia # E28

Diabetik Foot Care India #A26 Exevia is a market research and consulting company specialized in the healthcare market. Drawing on the extensive experience of the Diabetik Foot Care India Pvt Ltd, Chennai(INDIA) is a leading managing partners and together with our skilled team of project manufacturer and exporter of medical devices for the management of managers and analysts we cover the following healthcare areas: diabetes and its complications since last 27 years. DFCI is an EN:ISO • Pharmaceuticals and biologics 13485:2012 certified company and ventured in this domain to spread • Medical technology and diagnostics awareness and to help physician world-over, in fighting diabetes, by • Dentistry and oral health supplying quality medical devices at an affordable cost. 34 Countries Exevia provides consulting expertise for a range of pharmaceutical are using our products. and healthcare companies supporting them in addressing issues We distribute Non-Invasive Vascular Screening Devices, Neuropathy throughout the product lifecycle. Our goal is to go beyond simply Screening Devices, Foot Pressure Measurement systems, Podiatry and delivering results and help companies turn their insights into actions. Wound Care Therapy products which include Vascular Doppler for Our services cover both qualitative and quantitative research needs

21 using our in-house expertise in complex and creative methodologies. Hikma Pharmaceuticals #N34 With offices in the US, our headquarters in Germany and trusted We develop, manufacture and market a broad range of branded and partners worldwide, we serve the healthcare industry on an non-branded generic pharmaceutical products across the United international and local level. States (US), the Middle East and North Africa (MENA) and Europe. Exevia – Explore to Exceed Our operations span more than 50 countries and are conducted through three business segments. In the US, we have more than 2,000 Gabric # J37 employees. Our large state-of-the-art manufacturing facilities – one for sterile injectables and two for oral solids – supply a broad range Founded in 2006, Gabric is an Iranian NGO dedicated to improving of products in the US market. Hikma has nearly 5,000 employees in the lives of people with diabetes. To achieve this goal, we provide the MENA. We have local facilities in seven markets and sales and nation-wide diabetes education and support via conventional, as well marketing teams detailing doctors and pharmacists across 17 markets. as modern “real-time” solutions to the diabetic society, families, HCPs In Europe Hikma has nearly 700 employees in Europe – primarily and the public. in Portugal, Germany and Italy – where we have injectable Integrating advanced educational concepts e.g. “experiential manufacturing facilities. We are also a leading licensing partner in learning” into a patient-specific education path, succeeded by follow- MENA. Recently Hikma had signed a new Licensing agreement with up sessions and peer support is what distinguishes Gabric’s education Takeda Pharmaceuticals that includes its primary care portfolio related model. to Cardiometabolic disease area. This new license will transform Our unique “Diabetes school model” reaching out to 100.000+ Hikma CVD unit into a major provider and partner for HCPs while members across Iran, was recognized by WHO in 2016, presenting addressing the CVD patient journey in all its stages. Gabric as a “world leader” in diabetes. Our latest innovation, Kids™ Online Course, has gained vast popularity Imperial College London throughout the country and is expanding by day. This unique program Diabetes Centre #K20 has managed to unite education, counselling and peer support, utilizing Skype™ as well as Telegram™ messenger (mobile app) to Imperial College London Diabetes Centre (ICLDC), part of Mubadala’s provide real-time education and long-term support for people with network of world-class healthcare providers, is a state-of-the-art diabetes. outpatient facility that specialises in diabetes treatment, research, training and public health awareness. In just over a decade, the Centre Glenmark Pharmaceuticals Ltd # E26 has gained international renown for its holistic approach to the treatment of diabetes and related complications that enables patients Glenmark is a leading player in the discovery of new molecules both to receive the full spectrum of care they need in one place. NCEs and NBEs. Our branded generics business has a significant With more than 70 diabetes professionals and endocrinologists presence in markets across emerging economies including India. under one roof, ICLDC offers best-in-class medical attention from first The generics business services the requirements of developed markets diagnosis to disease management across 11 specialist practice areas like US and Western Europe. Our API business sells products in over including adult and paediatric endocrinology, treatment of metabolic 80 countries including the US, various countries in the EU, South and electrolyte disorders, pre- and post-bariatric surgery care, heart America and India. With 17 manufacturing facilities and 5 R&D disease prevention, nutritional advice, ophthalmology, nephrology and centers we are committed in creating ‘A new way for a new world’. podiatry. For more information, please visit www.icldc.ae

22 InBody #A10 to help patients and healthcare professionals better manage diabetes. Established in 1996, InBody is the global leader in body composition Since its inception, Dexcom has focused on better outcomes for analysis. By leading the field with cutting-edge technology and a patients, caregivers, and clinicians by delivering solutions that are best commitment to improvement and innovation, InBody has become in class. the most trusted name in BIA body composition analysis. All products As part of both their dedication and commitment to diabetes, Julphar are manufactured 100% in Korea and distributed to more than 60 and Dexcom have teamed up since 2013 in the MENA region to countries in globe. deliver solutions—while empowering the community to take control InBody is a premium body composition analyzer measuring muscles, of diabetes. fat and water with in 1 minute. By simply standing on and grabbing the handles, it directly accesses imbalance, deficits and health risks, LG Chem # M20 making it easier for users to select the most effective solution for diagnosis and prevention. Since its foundation in 1947, LG Chem has served as Korea’s representative chemical company, contributing to the development Insulin For Life #A18 of the national economy and the enhancement of the quality of life through continuous technological development, new product Insulin For Life (IFL) is a not-for-profit organisation that collects in- introduction, and quality innovation based on its stable growth. date unopened insulin and other diabetes supplies that are no longer In the business area of life sciences which LG Chem has focused needed, and donates them to clinics in disadvantaged countries to be on nurturing as a new growth engine of the future, LG Chem has given to children and adults with insulin requiring diabetes. developed one of the novel molecules in DPP-IV inhibitor class, IFL also provides diabetes supplies in the setting of disasters and Gemigliptin, has obtained marketing approval by worldwide Ministry supports diabetes camps in several countries. Since 1984 people with of Health since its launch in 2012. diabetes in over 80 countries in all IDF regions have been served. The LG Chem will continue to secure competitiveness in the global IFL network (IFL Global) includes collection and distribution centres market through aggressive investment and enhancement of its R&D in Australia, Austria, Canada, Croatia, Germany, Luxembourg, The capabilities based on its technological prowess that has succeeded in Netherlands, the USA and the United Kingdom. commercializing the drugs. Contact: www.insulinforlife.org, which has links to all affiliates. Lilly Diabetes # J30 Julphar / Dexcom #L30 Lilly has been a global leader in diabetes care since 1923, when we Established in 1980, Julphar is the largest generic pharmaceutical introduced the world’s first commercial insulin. manufacturer in the Middle East and North Africa region. Today, we are building upon this heritage by working to meet the In 2012 Julphar launched a 150 million-dollar Active Pharmaceutical diverse needs of people with diabetes and those who care for them. Ingredient (API) manufacturing facility –Julphar Diabetes– dedicated Through research and collaboration, a wide range of therapies, and a to producing raw material needed for insulin formulation. This continued determination to provide real solutions—from medicines positions Julphar among the largest manufacturers of insulin in the to support programs and more—we strive to make life better for all world, and the only one of its kind in the Middle East. Founded in those affected by diabetes around the world. For more information, 1999, Dexcom is transforming diabetes care and management by visit www.lillydiabetes.com providing superior continuous glucose monitoring (CGM) technology

23 Merck # L24 Neopharma # N30 Merck is a leading science and technology company in healthcare, At Neopharma; The 1st Abu Dhabi based manufacturing company life science and performance materials. Around 50,000 employees in UAE arena, innovation and quality blend to form world-class work to further develop technologies that improve and enhance pharmaceuticals. life – from biopharmaceutical therapies to treat cancer or multiple Neopharma has established itself as one of the most reputed and sclerosis, cutting-edge systems for scientific research and production, respected pharmaceutical manufacturing company in the region and to liquid crystals for smartphones and LCD televisions. In 2016, Merck currently caters to several geographies across Middle East, Africa, CIS, generated sales of €15.0 billion in 66 countries. Far East and South-East Asia with a presence in over 50 countries. Founded in 1668, Merck is the world’s oldest pharmaceutical and At Neopharma, ‘quality’ is the basic foundation on which products chemical company. The founding family remains the majority owner are developed and produced. At every stage of the production cycle, of the publicly listed corporate group. Merck holds the global rights quality stems from strict adherence to GLP/cGMP requirements. to the Merck name and brand. The only exceptions are the United Providing support to the whole framework is the latest set of States and Canada, where the company operates as EMD Serono, international quality systems incorporated from concept to commercial MilliporeSigma and EMD Performance Materials. production. Neopharma is developing and manufacturing a wide range of branded NeoBiocon # D26 generic and under-license products in different therapeutic areas and has a vibrant product development center that caters to both in-house NeoBiocon is one of the leading UAE’s pharmaceutical company and collaborative manufacturers’ need. focused on innovation to deliver affordable healthcare solutions to patients, partners and healthcare systems across the GCC. Novartis # L34 Established in the year 2009 as a joint venture of Biocon, a global biotechnology company based in India headed by Dr. Kiran Mazumdar Novartis provides innovative healthcare solutions that address the Shaw & the NMC group, UAE headed by Dr. B R Shetty, focused on evolving needs of patients and societies. Headquartered in Basel, unmet medical needs and offers novel therapies. Switzerland, Novartis offers a diversified portfolio to best meet these Today the company market more than 35 products in various needs: innovative medicines, cost-saving generic and biosimilar therapeutic categories and ranked amongst top 20 Pharmaceutical pharmaceuticals and eye care. companies of the UAE. With strong foot in cardiovascular segment, Novartis has leading positions globally in each of these areas. In NeoBiocon is No.1 generic company in the cardiovascular market 2016, the Group achieved net sales of USD 48.5 billion, while R&D of the UAE. The company also has solid presence in other segments throughout the Group amounted to approximately USD 9.0 billion. like Diabetes, Oncology, asthma & allergy management & gastric Novartis Group companies employ approximately 119,000 full-time- disorders to name a few. NeoBiocon demonstrates it’s commitment equivalent associates. Novartis products are sold in approximately 155 to increasing access to healthcare through far-reaching programs and countries around the world. For more information, please visit http:// partnerships. www.novartis.com.

24 Novo Nordisk A/S # J10/H10/H12/D16 capabilities, Owen Mumford produces class-leading medical devices in Novo Nordisk is a global healthcare company with more than 90 the field of diabetes that are used globally - exporting over 85% of its years of innovation and leadership in diabetes care. This heritage products to more than 60 countries worldwide. Selected as one of The has given us experience and capabilities that also enable us to help World Economic Forum’s Global Growth Companies, Owen Mumford people defeat other serious chronic conditions: haemophilia, growth is a trusted partner to many of the world’s biggest medical device disorders and obesity. diagnostic and pharmaceutical companies and works with international Headquartered in Denmark, Novo Nordisk employs approximately organisations to support customers at a local level and provide 41,400 people in 77 countries and markets its products in more than consistent and dedicated support. 165 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube Pic Solution # N20

Optomed Oy # J34 Pic Solution is an international leading healthcare brand. Its diabetes portfolio includes the new Insupen 34Gx3,5mm pen Optomed Oy (Ltd.) is a Finnish medical technology company that needle within a complete range of sizes from 33G to 29G. Their specializes in retinal imaging devices and solutions. Optomed’s Extr3me needle provides extra comfort while the High Flow TW mission is to make eye disease screenings available for everyone, enhances insulin flow. The range includes Insumed syringes, Digitest wherever needed. lancing devices and lancets, ReVita intensive treatment footcare range We develop and manufacture modern, mobile and easy-to-use retinal (sanitizer, lotion and cream) along with some patient’s accessories imaging devices that are suitable for any clinic for screening of various that complete the assortment. eye diseases, such as diabetic retinopathy, glaucoma and AMD. Optomed’s hand-held fundus cameras fulfill international ISO 10940 Roche Diabetes Care # L20 fundus camera standard requirements and are being used by private clinics, public hospitals, non-government organizations and charities Roche Diabetes Care has been a pioneer in providing innovation in around the world. Optomed’s products are registered and marketed in all diabetes technology and services for more than 40 years, helping major markets: Europe, USA, China, Russia, Japan, Korea, India and Brazil. people with diabetes to live their lives as active and unrestricted as possible. Owen Mumford #L35 Being a global leader in diabetes management, more than 5,000 employees in over 150 markets worldwide work every day to support Owen Mumford is a major medical device manufacturer that develops people with diabetes and those at risk, caregivers and healthcare pioneering medical devices for its own Owen Mumford brand and providers to optimally manage the condition – and more importantly custom device solutions for the world’s major pharmaceutical and achieve more time in the target range so they can experience true diagnostic companies. relief. Under the brand Accu-Chek and in collaboration with partners, Owen Mumford’s goal is to improve quality of life, encourage Roche Diabetes Care creates value by providing integrated diabetes adherence to treatment and reduce healthcare costs. Making a world management solutions to monitor glucose levels, deliver insulin of difference, to a world of people. and track relevant data points for successful glucose management. Owen Mumford’s goal is to develop solutions that address today’s By establishing a leading open digital platform, connecting devices healthcare demands. Through advanced research involving end-users and digital solutions, Roche Diabetes Care will enable personalized and health care professionals, and extensive design and manufacturing diabetes care and thus improve therapy outcomes.

25 Sanofi #G10 oral and gum problems. GUIDOR portfolio* assists professionals Company Name: SANOFI achieve a return to health of diseased or damaged tissues that City: PARIS support the dentition, with products to diagnostically test, clinically Country: FRANCE treat and surgically correct. Website: www.sanofi.com *Region dependent Building on our portfolio evolution, heritage and expertise, Sanofi www.sunstar.com has a focused business unit dedicated to delivering innovative, value-based medicines and integrated solutions in Diabetes and The Diabetes Centre # A22 Cardiovascular . We are committed to a collaborative approach with the goal of advancing scientific knowledge, driving the convergence Established in 2011, The Diabetes Centre (TDC) is a registered not- of science and technology, helping to improve outcomes and inspiring for-profit corporation, licensed to establish and maintain hospitals an evolution in care. and clinics all over Pakistan, particularly for diabetes and generally for other diseases. Servier # G20 Nationally, TDC is certified by Pakistan Centre for Philanthropy; whereas internationally, it is registered as a tax exempted charity in Servier is an independent French pharmaceutical company with UK and USA, and supported by the UAE Red Crescent in its mission. 21 000 employees in 148 countries. Our vision is to be recognised as a centre of excellence offering Servier’s commitment to innovative research underlines its mission comprehensive and compassionate care to diabetics in Pakistan. to provide therapeutic innovation to health care professionals and We strive to achieve this vision by providing excellent clinical services to improve patient care in diabetes, cardiovascular, neurologic, and to diabetic patients, irrespective of their ability to pay, with a focus psychiatric diseases, and cancer. With Intarcia (USA and Japan), Servier on quality and sustainability of care that would result in better is developing the first injection-free GLP-1 RA, which may change the clinical outcomes and improved quality of life; through fostering management of type 2 diabetes. and supporting education and training in diabetes management for the medical professionals; and by promoting public education and Sunstar Suisse SA # M40 awareness of diabetes.

Sunstar, a globally recognized leader in the oral care industry, has The European Association for been providing research-based products and services in 90 countries the Study of Diabetes # J35 for over 80 years. The company is committed to partnering with dental professionals The European Association for the Study of Diabetes e.V. (EASD) is and scientists to enhance the health and well-being of people a non-profit, medical scientific association and one of the largest everywhere and has been promoting research on the relationship networks for diabetologists worldwide. between periodontitis and systemic disease, such as diabetes, for It was founded in 1965 and its headquarters is based in Duesseldorf, more than 30 years. Today, under the motto “Always strive to help Germany. Our mission is to promote excellence in diabetes care people everywhere achieve better health and enhance their quality of through research and education and the aims are to encourage life,” Sunstar provides an extensive line of preventive and therapeutic and support research in the field of diabetes, the rapid diffusion of products under the brands GUM® and GUIDOR®. GUM offers a acquired knowledge and to facilitate its application. complete range of oral care products designed to prevent and control

26 The Searle Company Limited # J36 Tonghua Dongbao Pharmaceutical Ltd # F20 GD Searle started its operation in 1965 and divested its share to IBL Founded in 1985, Tonghua Dongbao Pharmaceutical Ltd. is a group in 1993, today Searle is almost in all the therapeutic categories conglomerate industrial group, actively engaged in the field of and now has evolved to the highly sophisticated biosimilars, IV pharmaceutical production and is now one of the pioneering solutions and Nutrition segments. manufacturers of recombinant biopharmaceuticals, especially Today, Searle is one of the leading pharmaceutical companies in recombinant human insulin. Pakistan with six state-of-the art cGMP compliant and purpose-built Through research and innovation, we take an active part in manufacturing facilities in Lahore and Karachi that manufacture and pharmaceutical and biotech development to make valuable pack products that ranges from Cough Suppressant to biosimilars. contribution to the world community. In Dongbao, innovative R&D With around 3000 knowledgeable, skilled And highly motivated programs, state-of-art technology facilities, rigorous quality control work force, led by a team of very high quality, highly accomplished systems, effectual marketing strategies as well as satisfactory after- professionals. sales services have been integrated into a well organised business Ranked as 4th largest on volumes, 6th largest on value and most operation system. importantly regarded as one of the Pakistan’s most prestigious and Since its establishment, Dongbao Group has demonstrated its respectable organization. As of the IMS Q4 MAT 2015, Searle’s commitment to improving people’s life and adding good value to compound annual growth of last two years has been astonishing. First the society. Due to its achievements, Dongbao is enjoying a sound time in the history of Pakistan Pharma Industry Searle has managed international recognition today and will endeavour to further its to leave behind US giant Pfizer and French Drug Maker Sanofi Aventis international collaboration. not only on ranking but on Value, Volumes, Growth and Market Share. [email protected] Trividia Health # F10

The World Diabetes Foundation # A12 Trividia Health is a global consumer health and Wellness Company based in Fort Lauderdale, Florida and a leading developer, The World Diabetes Foundation is an independent trust dedicated to manufacturer and marketer of advanced performance products for the prevention and treatment of diabetes in the developing world. people with diabetes. Its aim is to alleviate human suffering related to diabetes and its This includes a broad portfolio of blood glucose monitoring supplies complications among those least able to withstand the burden of the and technologies. From meters and tests strips, sharps, nutrition and disease. The Foundation supports sustainable partnerships and acts as skin care, each TRUE solution complements the next, forming one a catalyst to help others do more. powerful, and interconnected system to help people with diabetes From 2002 to March 2017, the World Diabetes Foundation provided keep the body in balance. With over 30 years of experience and 377 million USD in funding to 511 partnership projects in 115 dedication, Trividia Health, has become a leading supplier of co- countries, focusing on awareness, education and capacity building branded blood glucose monitoring systems to retailers throughout at the local, regional and global level. For every dollar spent, the North America and to a growing international audience. Our mission Foundation is able to raise approximately 2 dollars in cash or as in- is to provide affordable, innovative and advanced-performance kind donations from other sources. diabetes management systems for healthier lives. For more information, please visit www.worlddiabetesfoundation.org

27 WUWHS2020 #A16 Founded in 2000, WUWHS is the premier Wound care professional association and represents more than 90% of all practicing wound care specialists in the world. Our members are the wound care-related associations from every part of the world, more than 25.000 emailing contacts. The Association’s top priority is to raise and maintain the standard of the medical practice of wound care and improve its practice. WUWHS is working towards creation of the UAE edition of the World Congress as a highly innovative and valuable in contributing medical professions at all levels which includes physicians, nurses and all those who work in contact with skin wounds on a daily basis. It is crucial that the WUWHS 2020 be not just an opportunity for debate but also an important training opportunity for all. The 6th World Congress to be held in Abu Dhabi is from the March 8th to the 12th of March 2020.

28 29 Market leader in hand-held fundus imaging featuring Optomed Avenue, the new artificial intelligence for diabetic retinopathy screening

VISIT OPTOMED BOOTH #J34 www.optomed.com SATELLITE SYMPOSIUM

MONDAY 4 DECEMBER

Market leader in hand-held fundus imaging featuring Optomed Avenue, the new artificial intelligence for diabetic retinopathy screening

VISIT OPTOMED BOOTH #J34 www.optomed.com

31 B:210 mm T:200 mm S:160 mm

Learn more about BASAGLAR® at booths K 3 0 and0 J 3 0

® 1 S:174.6 mm B:210 mm BASAGLAR is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. T:200 mm Reference: 1. ABASAGLAR® [summary of product characteristics]. Eli Lilly Regional Operations GmbH., Kölblgasse 8-10, 1030, Vienna, Austria; 2014.

BASAGLAR KWIKPEN® ABBREVIATED PRESCRIBING the need for a change in insulin dose or an adjustment in concomitant be treated with oral carbohydrates. More severe episodes may be INFORMATION oral antidiabetic treatment. Do not dilute or mix BASAGLAR with any treated with intramuscular/subcutaneous glucagon or I.V. glucose BASAGLAR IS INSULIN GLARGINE (human insulin analogue) other insulin or solution. Do not administer BASAGLAR via an insulin infusion. For full details, please consult to full SPC. Adverse Reactions: Presentation: BASAGLAR is a clear, colourless, sterile solution of 100 pump or intravenously because severe hypoglycemia can occur. Adverse reactions commonly associated with BASAGLAR include units/mL (equivalent to 3.64 mg) insulin glargine (rDNA origin), available Hypoglycemia is the most common adverse reaction of insulin therapy, hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, as 3 mL KwikPen. Each pen contains 300 units of insulin glargine in including BASAGLAR, and may be life-threatening. Medication errors, pruritus, rash, edema and weight gain. Shelf life: 2 years. Before use: 3 mL solution. Therapeutic Indication: BASAGLAR is a long-acting such as accidental mix-ups between basal insulin products and other Store in a refrigerator (2°C – 8°C). Do not freeze. Do not store insulin analog indicated to improve glycemic control in treatment of insulins, particularly rapid-acting insulins, have been reported. Patients BASAGLAR next to the freezer compartment or a freezer pack. diabetes mellitus in adults, adolescents, and children aged 2 years and should be instructed to always verify the insulin label before each Shelf life after fi rst use: The medicinal product may be stored for a above. Dosage and Administration: The dose regimen (dose and injection. Severe life-threatening, generalized allergy, including maximum of 28 days up to 30°C and away from direct heat or timing) should be individually adjusted. BASAGLAR should be anaphylaxis, can occur. Discontinue BASAGLAR, treat and monitor until direct light. For full details of these and other side effects, please see administered once a day at the same time every day. It should only be symptoms resolve. A reduction in the BASAGLAR dose may be required the Summary of Product Characteristics, Date of Preparation or Last given by subcutaneous injection and should not be administered in patients with renal or hepatic impairment. As with all insulins, Review April 2016. Full Prescribing Information is Available From Eli Lilly intravenously. Consult full SPC for more details. BASAGLAR use can lead to life-threatening hypokalemia. Untreated and Company Limited, UAE Bldg. 25 – 6th Floor, Dubai Health Care Important Safety Information for BASAGLAR (insulin glargine hypokalemia may cause respiratory paralysis, ventricular arrhythmia, City, Dubai, UAE, P.O. Box: 25319 Tel: injection) 100 Units/mL: BASAGLAR is not recommended for the and death. Closely monitor potassium levels in patients at risk of (+971 4) 453 7800 Fax: (+971 4) 436 2399 You are encouraged to treatment of diabetic ketoacidosis. Contraindications: BASAGLAR is hypokalemia and treat if indicated. Cases of cardiac failure have been report negative side effects of Lilly prescription drugs through our contraindicated during episodes of hypoglycemia and in patients reported when pioglitazone was used in combination with insulin. If the pharmacovigilance department on this email: [email protected] hypersensitive to insulin glargine or one of its excipients. Warnings and combination is used, patients should be observed for signs and BASAGLAR (insulin glargine) is a registered trademark of Eli Lilly and Precautions: Insulin pens, needles, or syringes must never be symptoms of heart failure and pioglitazone discontinued if any Company. KWIKPEN® is a trademark of Eli Lilly and Company. shared between patients. Do NOT reuse needles. Monitor blood deterioration occurs. Pregnancy and Lactation: No clinical data from Reference: 1. BASAGLAR/ABASAGLAR EPAR by EMA - Summary of glucose in all patients treated with insulin. Modify insulin regimen controlled studies are available. The use of BASAGLAR may be product characteristics, http://www.ema.europa.eu/docs/en_GB/ cautiously and only under medical supervision. Changes in insulin considered during pregnancy, if necessary. For full details, please consult document_library/EPAR_-_Product_Information/human/002835/ strength, manufacturer, type, or method of administration may result in to full SPC. Overdose: Mild episodes of hypoglycemia can usually WC500175381.pdf UAEBAS2017-09-13T11_09_22

10718803_Global_IDF_JrnlAd_FR2.indd 1 9/15/17 3:34 PM

PREPARED BY AREA 23 Releasing as: PDFX1a Production: Laura Garcia x6950 Job #: 10718803 AD: Colors: 4C Client: BI/Lilly AE: Courtney Mcknight x2584 Product: Basaglar Bleed: 5 mm Producer: Sonnya Im x1787

Client Code: UAEBAS2017-09-13T11_09_22 Trim: 200 mm x 200 mm Digital Artist: NJ, BB, CL, CL, CL Safety: 20 mm left and right, Date: September 15, 2017 3:33 PM 12.7 mm top and bottom

Proof: FR2 M1 Spellcheck: CC FR Spellcheck: SJ Path: Area23:BI:BASAGLAR:10718803:Packaged_Jobs:10718803_Global_IDF_JrnlAd:10718803_Global_IDF_JrnlAd_FR2 4C Global IDF Convention Journal Ad This symposiumhasbeenpartiallysponsoredbytheBoehringer Ingelheimand Lilly Diabetes Alliance 14:20 13:30 12:40 12:30 12:30 -14:30 MONDAY 4DECEMBER 2017 Chair: Chair: Summary andclose Speaker: Patient Case#2: Beyond oral therapy: GLP-1receptor agonistsas potentialinjectableoptions Speaker: Speaker: Patient Case#1: The pathtoinsulin treatment Chair: Chair: Welcome andintroduction clinical andemotionalchallengesinT2DM Lilly -Thetransitiontoinjectabletherapies:Navigating Conference Hall A A. Jabbar (United Arab Emirates) M. Hassanein (United Arab Emirates) F. Giorgino (Italy) W. Polonsky (USA) M. Hassanein (United Arab Emirates) A. Jabbar (United Arab Emirates) M. Hassanein (United Arab Emirates) SATELLITE SYMPOSIUM 33 MONDAY SATELLITE SYMPOSIUM SATELLITE S. Kahn (USA) S. Kahn Emirates) Arab (United A. Alsheikh-Ali (USA) S. Kahn (Canada) S. Verma (United Kingdom) K. Khunti faculty All (USA) S. Kahn Chair: Chair: outcomes trials of cardiovascular in the era Diabetes management Speaker: lead us? can new evidence where in type 2 diabetes: and kidney disease Heart failure Speaker: in daily clinical practice Navigating the complexity of type 2 diabetes Speaker: practice Insights from inhibitors: Experience with SGLT2 Chair's summary Chair: Conference Hall A Hall Conference outcomes in cardiovascular - Improving Boehringer Ingelheim in practice 2 diabetes: Applying new evidence patients with type and introduction Welcome Chair: MONDAY 4 DECEMBER 2017 DECEMBER 4 MONDAY This symposium has been partially sponsored by the Boehringer Ingelheim and Lilly Diabetes Alliance Lilly Diabetes symposium has been partially sponsored by the Boehringer Ingelheim and This 15:40 16:00 16:30 16:50 17:20 15:30 - 17:30 15:30 34 MONDAY 17:20 17:00 16:40 16:20 16:00 15:40 15:30 15:30 -17:30 MONDAY 4DECEMBER 2017 Chair: Chairman's close Panel discussion Speaker: study andEXAMINE What’s therole of Alogliptin oncardiovascular benefitin T2DM: Perspective forSPEAD-A Speaker: Targeting insulinresistance: Pioglitazone10years datareview Speaker: Overview ofcardiovascular outcometrialsofglucose-loweringagents Speaker: What’s thebenefitofcombinationtherapy: Uniquevalueof Alogliptin/Pioglitazone Chair: Welcome andintroduction Takeda -Shapingthefuture oftype2diabetesmanagement:Whatnext? Conference HallB G. Schernthaner (Austria) R. Chilton (USA) S. Genovese (Italy) S. Rajagopalan (USA) G. Schernthaner (Austria) G. Schernthaner (Austria) SATELLITE SYMPOSIUM 35 MONDAY

SATELLITE SYMPOSIUM

TUESDAY 5 DECEMBER

37 VISIT L.20 NO. STAND US AT ACCU-CHEK COMPANION COMPANION FOR LIFE Be it pre-diabetes, its diagnosis or the everyday therapy management, management, everyday the therapy or Be pre-diabetes, it its diagnosis true offer that solutions supportsAccu-Chek with innovative you with diabetes. lives daily their in patients to your relief ACCU-CHEK is a trademark of Roche. Roche© 2017 Diabetes Care Roche Diabetes Care GmbH Sandhofer Straße 116 D - 68305 Mannheim SATELLITE SYMPOSIUM SATELLITE W. Kaplan (United Arab Emirates) Arab (United W. Kaplan (Germany) R. Hinzmann (Germany) S. Jacob (Germany) L. Heinemann (USA) S. Russell Chair: Chair: professionals for connecting patients and healthcare Using a digital platform Speaker: First T2D: (PDM) in patients with insulin-treated diabetes management Personalized study program learned out of the PDM-ProValue experiences and lessons Speaker: implantable CGM system and performance of the new Eversense® Features Speaker: Discussion and closing Conference Hall B Conference of integrated the future - Shaping Roche Diabetes Care solutions diabetes management Chair: TUESDAY 5 DECEMBER 2017 DECEMBER 5 TUESDAY 11:55 12:10 12:25 12:40 11:45 - 12:45 11:45 Introduction 38 TUESDAY ACCU-CHEK COMPANION FOR LIFE

Be it pre-diabetes, its diagnosis or the everyday therapy management, Accu-Chek supports you with innovative solutions that offer true relief to your patients in their daily lives with diabetes.

VISIT US AT STAND NO. L.20

ACCU-CHEK is a trademark of Roche. © 2017 Roche Diabetes Care Roche Diabetes Care GmbH Sandhofer Straße 116 D - 68305 Mannheim

39 SATELLITE SYMPOSIUM SATELLITE N. Kanumilli (United Kingdom) (United N. Kanumilli (Turkey) M. Akçay Kingdom) (United N. Kanumilli Arabia) Slail (Saudi F. Al Addressing influenza in people living with diabetes - Why should this matter? Why living with diabetes - influenza in people Addressing Speaker: do we stand? Where of influenza and diabetes: Clinical management Speaker: Arabia Saudi people living with diabetes against influenza - Lessons learned from Protecting Speaker: Summary and close Diabetes Spotlight with of influenza on people living Sanofi Pasteur - Impact threat and under-appreciated diabetes: A serious Chair: TUESDAY 5 DECEMBER 2017 DECEMBER 5 TUESDAY 12:10 12:25 12:40 12:55 12:00 - 13:00 12:00 Introduction 40 TUESDAY 19:25 19:15 19:00 18:45 18:30 18:15 18:00 17:45 17:30 17:30 -19:30 TUESDAY 5DECEMBER 2017 Chair: Summary andclose Panel discussion: Bringingprecision tothechoiceoftherapy in Type 2diabetes Speaker: Glucose-lowering therapies andcardiovascular mortality: Where are wenow? Speaker: What doweneedtoknow when choosingafirst injectablein Type 2diabetes? Speaker: Optimising safetyinpractice withSGLT2 inhibitors Speaker: What elseislefttolearnabout thenon-glycaemiceffectsofSGLT2 inhibitors? Speaker: Should weofferearly, tightanddurable glycaemiccontrol topatientswith Type 2diabetes? Chair: Chair: Introducing precision medicinein Type 2diabetes Arrivals andrefreshments AstraZeneca -Precision medicine forType 2diabetes ICC 1 J. Vora (UnitedKingdom) Co-chairs andspeakers N. Sattar (UnitedKingdom) F. Knop (Denmark) W. Hanif (UnitedKingdom) F. Giorgino (Italy) M. Hassanein (United Arab Emirates) J. Vora (United Kingdom) K. Khunti (UnitedKingdom) SATELLITE SYMPOSIUM 41 TUESDAY SATELLITE SYMPOSIUM SATELLITE S. Kahn (USA) S. Kahn Emirates) Arab (United T. Fiad (USA) J. Campbell (United Kingdom) C. Bailey Gitt (Germany) A. Emirates) Arab (United T. Fiad Kahn and Faculty S. Chair: Chair: to learn? more Is there activity at the cellular level: of incretin New science in the understanding Speaker: both in The importance of addressing complications: and macrovascular Microvascular our patients with type 2 diabetes Speaker: Speaker: for patients with type paradigm treatment fit within today’s do DPP-4 inhibitors Where patients The latest data and implications for our 2 diabetes? Speaker: patients with type 2 diabetes: of in the individualized treatment Clinical considerations patient case discussion An interactive Speaker: Final comments and summary ICC 4 new science DPP-4 inhibition: Understanding MSD - 10 years of patients with type 2 diabetes for and clinical treatment remarks Chair welcome and opening Chair: TUESDAY 5 DECEMBER 2017 DECEMBER 5 TUESDAY 17:35 17:50 Q&A 17:55 18:25 18:50 Q&A 18:55 19:25 17:30 - 19:30 17:30 42 TUESDAY 19:25 19:05 18:45 18:30 18:20 18:00 17:45 17:35 17:30 17:30 -19:30 TUESDAY 5DECEMBER 2017 Chair: Closing remarks Breaking through thebarriers toeffectiveglycemiccontrol Panel discussion Speaker: A closerlookatfixed-ratio combinationtherapy Speaker: Fixed-ratio combinationtherapy forearly, effectivecontrol: theLixiLan-Oand-Lstudies Speaker: Simultaneous vs. stepwise: therationale forearlycombination therapy Fixed-ratio combination therapy: anewapproach to T2DM management Speaker: Basal insulintherapy with Gla-300: evidencefrom thereal world Speaker: Need forearlierinsulininitiationandcontinuoustitration Speaker: Looking across theevidence spectrum: from RCTtoRWE Innovations inbasalinsulin: insightsfrom thereal world Chair: Welcome andintroduction glycemic control inType 2diabetes Sanofi -Evolvingstrategiesforearly,effective Conference Hall A H. Ezzeddin (United Arab Emirates) Facutly andRaconteurLori Berard J.P. Frías (USA) P. Mora (USA) J.P. Frías (USA) A. Cheng (Canada) D. Mauricio(Spain) N. Freemantle (UnitedKingdom) H. Ezzeddin (United Arab Emirates) SATELLITE SYMPOSIUM 43 TUESDAY SATELLITE SYMPOSIUM SATELLITE A. Ceriello (Italy) A. Ceriello (Italy) A. Ceriello (Sweden) L. Landstedt-Hallin (Qatar) S. Atkin (Mexico) R. Mehta Emirates) Arab (United M. Hassanein (Italy) A. Ceriello therapy The evolution of insulin Speaker: insulins action of next generation The mode of Starting point: Speaker: acting insulin risk with ultra-long hypoglycemia Evidence of reducing Speaker: Changing the insulin intensification paradigm Speaker: during and after Ramadan before, Insulin treatment Speaker: Summary and closing remarks Chair: Conference Hall B Conference in type 2 diabetes of ultra-long acting insulins - Next generation Novo Nordisk Chair: TUESDAY 5 DECEMBER 2017 DECEMBER 5 TUESDAY 17:30 17:45 18:05 18:30 18:55 19:15 Q&A 19:25 17:30 - 19:30 44 TUESDAY 19:00 Q&A 18:45 18:30 18:15 17:45 17:40 Introduction 17:30 -19:30 TUESDAY 5DECEMBER 2017 Speaker: PalestinianOccupied Territory Case study: Comprehensive modelofeyecare forvulnerable populationsinthe Speaker: Speaker: Case study: Integrated modelsforDRcare inChina Speaker: Case study: Integrated modelsofcare forDRinIndia Speaker: Diabetes, eyehealthandNCDcare: The caseforintegration Chair: Chair: Chair: Advancing anintegratedmodelofqualityeyecare, diabetesandNCDs Capital Suite1 N. Mikki (Palestine ) N. Fong (China) N. Congdon (USA) G.V.S. Murthy(India) W. Mathenge (Rwanda) J. Brumby (Australia) N.(Korea) Cho J. Brumby(Australia) SATELLITE SYMPOSIUM 45 TUESDAY SATELLITE SYMPOSIUM SATELLITE E. Montanya (Spain) E. Montanya (Sweden) L. Mellbin Kingdom) (United J. Deanfield (Germany) J. Mann (Denmark) F. Knop (Brazil) R. Réa (United Kingdom) J. Deanfield (Spain) E. Montanya we in 2017? are where in type 2 diabetes: risk management Cardiovascular Speaker: shift? a paradigm in type 2 diabetes: outcome trials Cardiovascular Speaker: agonists with GLP-1 receptor Long-term clinical and metabolic outcomes Speaker: effects beyond glycaemia system: agonists and the cardiovascular GLP-1 receptor Speaker: two perspectives to patient care: Bridging trial results Speaker: Speaker: discussion Panel Meeting close Chair: Hall 11 trials: closing outcome - Cardiovascular Novo Nordisk of type 2 diabetes? a gap in management and introduction Welcome Chair: TUESDAY 5 DECEMBER 2017 DECEMBER 5 TUESDAY 18:35 18:55 19:15 19:35 19:55 20:10 20:25 18:30 - 20:30 18:30 46 TUESDAY TRAJENTA_PRESS_AD_vectors.indd 2 13/09/17 15:26

SATELLITE SYMPOSIUM

WEDNESDAY 6 DECEMBER

49 SATELLITE SYMPOSIUM SATELLITE I. Ksseiry (United Arab Emirate) Arab Ksseiry (United I. Chan (Chin) J. (United Kingdom) Strain D. Clinical inertia and how to overcome barriers to early treatment intensification to early treatment barriers to overcome Clinical inertia and how Speaker: in type 2 diabetes clinical inertia Addressing Speaker: Conference Hall B Conference Clinical Inertia: When and how Novartis - Fighting & introduction Welcome Chair: WEDNESDAY 6 DECEMBER 2017 DECEMBER 6 WEDNESDAY 11:50 12:10 12:30 Q&A 11:45 - 12:45 11:45 50 WEDNESDAY 12:50 12:30 12:05 12:00 12:00 -13:00 WEDNESDAY 6DECEMBER 2017 Chair: Q&A andclosingremarks Speaker: Characteristics and patternsofcare fordiabetespatientsduringRamadan–aprospective study Speaker: Speaker: Basal insulin: anessentialdialoguebetweenevidenceandclinicalpractice Chair: Welcome andintroduction Sanofi -Let’s talkaboutbasalinsulin:takingathree-dimensional approach Diabetes Spotlight A. Philis-Tsimikas(USA) M. Hassanein(United Arab Emirates) A. Philis-Tsimikas(USA) A.(Canada) Cheng A.(Canada) Cheng SATELLITE SYMPOSIUM 51 WEDNESDAY SATELLITE SYMPOSIUM SATELLITE A. Al A. Madani (United Arab Emirates) (USA) S. Adi (Switzerland) L. Krinelke

A practical and clinical application of continuous glucose monitoring (CGM) of continuous glucose monitoring and clinical application A practical patients requiring with intensive insulin Speaker: Speaker: Diabetes Spotlight (CGM): Continuous glucose monitoring Dexcom/Julphar - for glucose monitoring of care standard The emerging global Chair: WEDNESDAY 6 DECEMBER 2017 DECEMBER 6 WEDNESDAY 13:30 13:30 - 14:30 52 WEDNESDAY 19:05 Conclusion 18:45 18:15 17:55 17:35 17:30 Introduction 17:30 -19:10 WEDNESDAY 6DECEMBER 2017 Speaker: Panel discussion Speaker: A novelapproach toimproving adherence andpatientoutcomes in T2D Speaker: How doesadherence impacttreatment success? Speaker: Achieving betterglycemiccontrol: Unmetneedsandmainbarriers Speaker: Chair: Chair: Servier -Tackling unmetneedsintype2diabetes:Evolvingperspectives Conference Hall A R. Henry (USA) R. Henry (USA) F. Snoek (The Netherlands) K. Khunti (UnitedKingdom) A. Al Madani(United Arab Emirates) R. Henry (USA) A. Al Madani(United Arab Emirates) SATELLITE SYMPOSIUM 53 WEDNESDAY SATELLITE SYMPOSIUM SATELLITE S.L. Atkin (Qatar) S.L. (Germany) T. Heise (Austria) T. Pieber (Canada) V. Woo Rodbard (USA) H.W. Atkin (Qatar) S.L. Pharmacological performance of faster aspart Pharmacological performance Speaker: faster aspart on endogenous glucose production Physiological effect of Speaker: type 2 diabetes to clinical benefits in type 1 and clinical pharmacology from onset programme: Speaker: Speaker: discussion Panel Meeting close Chair: Conference Hall B Conference of ultra-fast insulins - The pursuit Novo Nordisk and introduction Welcome Chair: WEDNESDAY 6 DECEMBER 2017 DECEMBER 6 WEDNESDAY 17:40 18:05 18:30 19:00 19:25 17:30 - 19:30 17:30 54 WEDNESDAY 19:25 19:20 Discussion 18:55 18:50 Discussion 18:30 17:50 17:45 17:40 17:30 17:30 -19:30 WEDNESDAY 6DECEMBER 2017 Chair: Chair: Summary andclose Speaker: Diabetes andheartfailure: From unexpectedresults totreatment targets Speaker: ACE-Trial: Resultsandimplications Chair: Diabetic complications: Challengesandopportunities Speaker: Lecture ofawardee: The renaissance ofglycaemology Chair: Laudation andpresentation ofawardee Video messagebyHellmut Mehnert Chair: Introduction to theaward Mehnert Award Hellmut Challenges andopportunities,HellmutMehnertAward D&CVD EASDStudyGroup & ForschergruppeDiabetes-Diabeticcomplications: Capital Suite1 O. Schnell (Germany) R. Holman (UnitedKingdom) I. Raz (Israel) E. Standl (Germany) O. Schnell (Germany) A. Ceriello (Italy) R. Holman (UnitedKingdom) R. Holman (UnitedKingdom) SATELLITE SYMPOSIUM 55 WEDNESDAY 56 SATELLITE SYMPOSIUM

THURSDAY 7 DECEMBER

57 58 12:55 12:45 Q&A 12:25 12:05 12:00 12:00 -13:00 THURSDAY 7DECEMBER 2017 Chair: Closing remarks Speaker: Case study: combinationtherapy intheclinic Speaker Individualizing care through titratable fixed-ratio combinationtreatment approaches Chair: Welcome andintroduction Sanofi -Fixed-ratiocombinations:apracticalapproach toindividualisedcare Diabetes Spotlight L. Berard (Canada) All P. Mora (USA) J.P. Frías (USA) L. Berard (Canada) SATELLITE SYMPOSIUM 59 THURSDAY International Hypoglycaemia Study Group

We identify new and emerging issues and insights about hypoglycaemia from within the scientific community

We formulate a comprehensive scientific communications platform with which to enhance scientific understanding of hypoglycaemia

We strive to highlight the significance of hypoglycaemia as a barrier to optimal glycaemic control at the practitioner and patient levels

Please join us to see four of the IHSG members present Hypoglycaemia: a practical approach to a global problem Diabetes Spotlight - Exhibition Hall 7 December 2017 - 13.30-14.30 Chair Speakers

Simon Heller Kamlesh Khunti Brian Frier Sophia Zoungas BA, MB, BChir, DM, FRCP PhD, MD, FRCGP, FRCP MD, FRCPE MBBS (Hon), FRACP, PhD

60ihsgonline.com

50685_BloodDrop_Ad.indd 1 10/27/17 10:28 AM 14:05 13:55 13:45 13:35 13:30 Introduction 13:30 -14:30 THURSDAY 7DECEMBER 2017 Panel discussion Speaker: Classification andclinicalimplications Speaker: Prevention and treatment Speaker: Global prevalence and impact Speaker: Hypoglycaemia: apracticalapproach toaglobalproblem HypoglycaemiaStudyGroupInternational - Diabetes Spotlight S. Zoungas (Australia) B. Frier (UnitedKingdom) K. Khunti (UnitedKingdom) S. Heller (UnitedKingdom) SATELLITE SYMPOSIUM 61 THURSDAY SATELLITE SYMPOSIUM SATELLITE S. Taheri (Qatar) S. Taheri (USA) D. Ryan (Australia) J. Proietto le Roux (Ireland) C. (Qatar) S. Taheri Why should we treat obesity? should we treat Why Speaker: to weight loss Hormonal adaptations Speaker: GLP-1 receptor weight and comorbidities via the Targeting Speaker: discussion Panel Meeting close Chair: Conference Hall B Conference via the GLP-1 receptor weight and comorbidities - Targeting Novo Nordisk and introduction Welcome Chair: THURSDAY 7 DECEMBER 2017 DECEMBER 7 THURSDAY 17:40 18:05 18:25 19:05 19:25 17:30 - 19:30 17:30 62 THURSDAY